The molecule was never the asset. The cream was.
On 3 September 2026, Organon LLC, Organon International GmbH and Dermavant Sciences GmbH sued Dr. Reddy's Laboratories over a proposed generic version of VTAMA (tapinarof) cream 1%. Tapinarof itself has been known for years and its early patent family expired in 2020. What protects the product is a formulation patent running to 2036, and its owner told investors five years ago that generics would have to either invalidate it or design around it. Case 2:26-cv-11431 (D.N.J.), before Judge Claire C. Cecchi. Docket, USPTO record and SEC filings reviewed 14 September 2026. The complaint was not reviewed; it is available through PACER.
Making tapinarof work as a cream
By the time of the invention the hard part was no longer discovering tapinarof. The active ingredient was known, and so was the general idea of putting stilbene compounds into topical emulsions. What remained unsolved was producing a stable, homogeneous and pharmaceutically acceptable formulation that could carry tapinarof without relying on conventional petrolatum and mineral-oil systems.
The answer was formulation engineering rather than chemistry: a medium-chain triglyceride oil phase to solubilise the active, a non-ionic emulsifying system, and a controlled oil and water composition. Further work on active concentration, excipient levels, homogeneity and droplet size turned "tapinarof in an emulsion" into a defined pharmaceutical cream.
The significance lies in bridging a known active ingredient and a commercially usable medicine.
The owner said out loud what the patent was for
This is the part that makes the case predictable in hindsight. In 2021, while Dermavant was still a Roivant company, its investor materials described the formulation patent in terms that read now like a forecast of this litigation.
The patent was said to cover the viable emulsion and cream formulations studied by GSK, its predecessor and their contract research organisations over years of development, with broad ranges on the critical components, covering the commercial formulation and variations of it. The stated consequence was blunt: ANDA filers "would have to invalidate or design-around these patents" to reach the market before expiry.
Two other patents were named alongside it in the same disclosure, and all three were described as potentially eligible for Orange Book listing.
| Patent | Covers | Natural expiry |
|---|---|---|
| US 10,195,160 | The topical oil-in-water formulation. 113 claims directed to homogeneous micro-emulsions containing tapinarof, a medium-chain triglyceride oil phase and a surfactant, substantially free of petrolatum and mineral oil. | 2036 |
| US 10,426,743 | Methods of treating inflammatory diseases, including plaque psoriasis and atopic dermatitis, using the formulations of the '160 patent. | 2036 |
| US 10,647,649 | The commercial API synthesis, novel intermediates and the high-purity crystal form produced by it. | 2038 |
The docket for this case does not yet carry a Form AO-120 report identifying the patents in suit, so the asserted set is not confirmed by the court record. The complaint was filed with twelve exhibits. Which of these three are being asserted, and which are being held back, is the first thing worth establishing.
From a 2015 priority date to a generic challenge
Roughly a decade of the protected term has already run. Ten years remain, which is what a generic challenger is trying to shorten.
Two paths, one molecule
More than one group was working to turn the same active ingredient into a practical topical medicine. In China, the tapinarof and benvitimod programme produced a twice-daily oil-in-water cream, approved in 2019 for mild to moderate plaque psoriasis. In parallel, the GSK and Stiefel line that became Dermavant pursued a different formulation strategy, which became VTAMA 1%, a once-daily cream with a different excipient system.
That distinction matters commercially. The question was not whether tapinarof could be formulated as a cream, but whether a formulation could deliver a differentiated, stable and convenient product. The later VTAMA formulation represents a separate optimisation path rather than a reproduction of the earlier Chinese cream.
The surrounding research had already established several of the building blocks. Researchers at Hebei University of Science and Technology had shown that the same active, 3,5-dihydroxy-4-isopropylstilbene, could be carried in a topical microemulsion. Work at STC.UNM and elsewhere explored oil-in-water emulsions and nanoemulsions for stilbene compounds, alongside separate lines on emulsion stability, lipid-based solubilisation, surfactant systems and droplet-size control.
The subject invention is best read as the point where those strands were selected and combined for one specific active, rather than as the introduction of a new formulation concept. That is also precisely the ground on which a generic challenger would attack it.
Where the value actually sits
VTAMA was approved in May 2022 for plaque psoriasis in adults, with a supplemental application for atopic dermatitis following. Organon acquired Dermavant in October 2024 specifically to bring the product into its dermatology portfolio. The marketed cream contains tapinarof with medium-chain triglycerides, emulsifying wax and a surfactant system, closely tracking the formulation themes of the 2015 development work.
So the May 2015 priority date is more than a family milestone. It marks the transition from molecule-focused development to product-defining formulation intellectual property, and it is that property, rather than the active ingredient, that stands between the branded product and a generic.
What the outcome turns on is claim construction. This analysis works from the public record, the patent family disclosures and the prosecution history as described by the owner; the claim text itself has not been examined here, and with 113 claims in the formulation patent alone, the scope question is substantial. Whether Dr. Reddy's proposed product falls inside those claims, and whether the claims survive a validity challenge grounded in the earlier microemulsion and stilbene-emulsion work, are the two questions the case will answer.
Common questions
Who is suing whom, and where?
Organon LLC, Organon International GmbH and Dermavant Sciences GmbH filed against Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. in the U.S. District Court for the District of New Jersey on 3 September 2026, case 2:26-cv-11431, before Judge Claire C. Cecchi. It is an ANDA case under 35 U.S.C. section 271, with no jury demand.
Which patent is at issue?
The case summary identifies U.S. Patent No. 10,195,160, the tapinarof formulation patent. The docket does not yet carry a Form AO-120 report confirming the full list of asserted patents, and the complaint was filed with twelve exhibits, so further patents may also be in suit.
When does the VTAMA formulation patent expire?
The '160 formulation patent has a natural expiration date in 2036, before any patent term adjustment or extension. A related method-of-use patent, US 10,426,743, shares that date, and an API synthesis patent, US 10,647,649, runs to 2038.
What does the formulation patent actually cover?
It contains 113 claims directed to topical, homogeneous, oil-in-water micro-emulsions containing tapinarof, an oil phase of medium-chain triglycerides, a surfactant and other specified ingredients, substantially free of petrolatum and mineral oil.
Why is formulation intellectual property so important here?
Tapinarof itself was already known, and the early patent family covering its use expired in 2020. The commercial differentiation moved from the active ingredient to how it was formulated into a stable, convenient and usable topical product, which is where the remaining exclusivity sits.
Had the patent owner anticipated a generic challenge?
Investor disclosures from 2021 described the formulation patent as covering the viable emulsion and cream formulations developed over years of work, with broad ranges on critical components, and stated that ANDA filers would need to invalidate or design around the patents to reach the market before expiry.
Does this article establish that Dr. Reddy's infringes?
No. It describes the patent family, the public record and the commercial context. It makes no infringement, validity or enforceability determination, and no court has ruled on any of these questions.
